These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21036266)

  • 1. Intensive treatment of hyperglycaemia: what are the objectives?
    Yudkin JS; Richter B; Gale EA
    Lancet; 2010 Oct; 376(9751):1462-3. PubMed ID: 21036266
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensive treatment of hyperglycaemia: ACCORD.
    Klein R
    Lancet; 2010 Aug; 376(9739):391-2. PubMed ID: 20594590
    [No Abstract]   [Full Text] [Related]  

  • 3. [Intensive glucose control in type 2 diabetes is beneficial].
    Nilsson PM; Attvall S
    Lakartidningen; 2009 Sep 2-8; 106(36):2198. PubMed ID: 19817174
    [No Abstract]   [Full Text] [Related]  

  • 4. [Intensive glycemia control of type-2 diabetes mellitus: a real A(D)VANCe or a deep dis(ACCORD)?].
    Lambiel J; Fumeaux T
    Rev Med Suisse; 2008 Aug; 4(166):1734. PubMed ID: 18777740
    [No Abstract]   [Full Text] [Related]  

  • 5. Postprandial hyperglycaemia--its importance and implications.
    Lüddeke HJ
    Int J Clin Pract Suppl; 1999 Jul; 104():3-7; discussion 18-20. PubMed ID: 12669731
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical significance, pathogenesis, and management of postprandial hyperglycemia.
    Gerich JE
    Arch Intern Med; 2003 Jun; 163(11):1306-16. PubMed ID: 12796066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Near-norm blood sugar regulation in diabetes. Myocardial infarct rate halved].
    MMW Fortschr Med; 2005 Sep; 147(35-36):4-5. PubMed ID: 16180560
    [No Abstract]   [Full Text] [Related]  

  • 8. Summaries for patients. Control of blood sugar in type 2 diabetes: a guidance statement from the American College of Physicians.
    Ann Intern Med; 2007 Sep; 147(6):I52. PubMed ID: 17876018
    [No Abstract]   [Full Text] [Related]  

  • 9. [Intensive glucose control in type 2 diabetes. The benefit greater than the risks?].
    Rydén M; Freyschuss B
    Lakartidningen; 2008 Oct 15-21; 105(42):2910-1. PubMed ID: 19025147
    [No Abstract]   [Full Text] [Related]  

  • 10. 1,5-anhydro-D-glucitol: a novel marker of glucose excursions.
    Dworacka M; Winiarska H; Szymanska M; Kuczynski S; Szczawinska K; Wierusz-Wysocka B
    Int J Clin Pract Suppl; 2002 Jul; (129):40-4. PubMed ID: 12166605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications.
    Ceriello A
    Diabetologia; 2003 Mar; 46 Suppl 1():M9-16. PubMed ID: 12652353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Blood glucose control in type 2 diabetes. Basic requirements for reducing vascular complications].
    Seissler J
    Internist (Berl); 2007 Jul; 48(7):676, 678-80, 682 passim. PubMed ID: 17541528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreasing complications in type 2 diabetes.
    Greenawald MH; Schaffer RS; Jeremiah MP
    J Fam Pract; 1998 Apr; 46(4):278-9. PubMed ID: 9564363
    [No Abstract]   [Full Text] [Related]  

  • 14. ADVANCE and glycaemia thresholds: a need to clarify the statistical approach.
    Currie CJ
    Diabetologia; 2012 Aug; 55(8):2298-9; author reply 2300. PubMed ID: 22610398
    [No Abstract]   [Full Text] [Related]  

  • 15. Blood glucose control and microvascular complications--what do we do now?
    Dahl-Jørgensen K; Brinchmann-Hansen O; Bangstad HJ; Hanssen KF
    Diabetologia; 1994 Dec; 37(12):1172-7. PubMed ID: 7895945
    [No Abstract]   [Full Text] [Related]  

  • 16. Guideline adaptation: an appealing alternative to de novo guideline development.
    Palda VA; Graham ID; Davis D; Burgers J; Brouwers M; Cluzeau F;
    Ann Intern Med; 2008 Apr; 148(7):564; author reply 564-5. PubMed ID: 18378957
    [No Abstract]   [Full Text] [Related]  

  • 17. Guideline adaptation: an appealing alternative to de novo guideline development.
    Fervers B; Remy-Stockinger M; Graham ID; Burnand B; Harrison M; Browman G; Latreille J
    Ann Intern Med; 2008 Apr; 148(7):563-4; author reply 564-5. PubMed ID: 18378955
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperglycemia and cardiovascular risk in NIDDM.
    Uusitupa MI; Niskanen LK
    Diabetes Care; 1995 Jun; 18(6):884-5. PubMed ID: 7555522
    [No Abstract]   [Full Text] [Related]  

  • 19. [2008--The year of the big studies about the therapy of type-2-diabetes. ACCORD, ADVANCE, VADT, and the UKPDS 10-year follow-up data].
    Schatz H
    MMW Fortschr Med; 2009 Mar; 151(12):42-3. PubMed ID: 19475859
    [No Abstract]   [Full Text] [Related]  

  • 20. [Tissular toxicity of glucose and therapeutic perspectives].
    Larger E; Marre M
    Rev Prat; 2001 Oct; 51(16):1765-8. PubMed ID: 11795119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.